There is scant information about the incidence of urinary tract infection in men with urethral strictures. The aim of this study was to investigate the prevalence and phenotypes of pathogens among adult patients with urethral stricture diseases.METHODS: This is a cross-sectional study, which was conducted at a high volume tertiary center for the management of urethral diseases between September 2014 to December 2015. Cases of interest were all the adult patients with urethral stricture diseases, who were scheduled for surgery and underwent a urine samples before the surgery. The primary end-point was to determine the prevalence of urinary tract infection, defined as a urine culture positive: 1 Â 105 colony forming units/ml. The secondary end-point was to investigate the phenotypes of isolated pathogens.RESULTS: Overall 386 patients (mean age 56.6 years, range 14 -84) were included in the study. The prevalence of urinary tract infection was 32.1% (124/386); the highest prevalence was observed in age range between 60-69 years, while the lowest in younger men. The most frequent phenotype was E. coli 46% (57/124), followed by Enterococcus 21% (26/124). All data are summarized in table 1 and 2. CONCLUSIONS: We found a high prevalence of UTI in men with urethral stricture, who were scheduled for surgery. The prevalence was higher in elderly patients than in younger and the most frequent pathogen was E. Coli followed by the Enterococcus. Both the observation could have clinical implications and prompt further genotyping studies.
on overall survival (OS) and recurrence free survival (RFS). P value < 0.05 was considered statistically significant.RESULTS: Baseline patient characteristics and OSS treatment type are summarized in Table 1. Among 129 patients the most commonly performed OSS was combined excisional/laser treatment (34.1%). One patient had a positive surgical margin postoperatively. 69.8% of patients presented with pT1a disease and 87.6% did not have palpable inguinal adenopathy. 72.2% of patients undergoing nodal dissection were pN0. 21 patients had disease recurrence with 14 (10.8%) exhibiting local recurrence at 15.1 mos. (range 0.33-138.0). Salvage treatments included glans sparing surgery (71.4%), nodal dissection (32.8%) and radical surgery (0.48%). 3 patients developed metastatic disease and died. Median follow up for the group was 28.0 mos. (range 0.17-188.2). 66 patients had a minimum follow up greater than 24 mos. Of these, 12 (18%) presented with local recurrence at a median recurrence free interval of 22.9 mos. (range 2.2-64.9), and median follow up of 65.8 mos. (range 25.1-188.2). Median OS and RFS were 136.7 and 138.8 mos., respectively. Shaft tumor location was the only predictor of worse OS (p[0.046). Pathologic lymph node metastases (p[0.016) and higher T stage (> pTis, p[0.023) were associated with recurrence.CONCLUSIONS: OSS using a variety of techniques provides long-term effective local control for low stage penile cancer in the setting of negative surgical margins. Long-term follow-up of the primary tumor is essential to detect delayed recurrence.
mean follow-up of 33 (12-76) months. In the two cases not undergoing completion ILND following positive identification of micro-metastases, one had isolated tumour cells and had no evidence of recurrence at 11 months. The second patient developed progressive disease from the contralateral side.CONCLUSIONS: Patients undergoing SLNB that shows micrometastases are unlikely to have further disease in completion ILND samples, and unlikely to have local recurrence. However, it is not yet possible to recommend avoiding completion ILND in such patients. eUROGEN will work towards a large multicentre study to answer this important question.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.